Sincethe autumn of 2012, the Board of ONCOloghas worked to find buyersfor the sale ofthe entire company or itsassets.However, these effortshave not been successfulandthe ONCOlogBoard has therefore notseen anyalternative left but toapply forthe company to bedeclared bankrupt.

Allenexowns14.9% ofONCOlog, but has since mid-2011changed its focustoinclude the transplantationarea only.Allenexhassince this strategic shiftnotfinanced ONCOlog in any way. Therefore, the ONCOlogbankruptcywill not have anyeffect on Allenex`financial results. This is due to the fact that the Allenex holding in ONCOlogisalready valued at zero andthat noother commitmentsexist.

For more information please contact:
 Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail: anders.karlsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on May 08, 2013, at 12.45 CET.Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market.Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.

distributed by